PENNINGTON, N.J. and
SAN DIEGO, April 15, 2021 /PRNewswire/ -- OncoSec
Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a
biotechnology company focused on cytokine-based intratumoral
immunotherapies, today announced that it will be presenting encore
interim data from its KEYNOTE-695 registration-enabled Phase
2b clinical trial evaluating TAVO™
(tavokinogene telseplasmid), a DNA plasmid-based interleukin-12
(IL-12), in combination with KEYTRUDA® (pembrolizumab)
in rigorously defined anti-PD1 checkpoint resistant metastatic
melanoma patients at the 10th World Congress of
Melanoma. This is an encore presentation of data presented at The
Society for Immunotherapy of Cancer's (SITC) 2020 Annual Meeting.
Presenters will also discuss the therapeutic potential of OncoSec's
DNA medicines platform to elicit robust anti-tumor immunity via
intratumoral gene electrotransfer of TAVO plus CXCL9.
"Achieving an overall response rate of 30% with several complete
responses and no serious adverse events is extremely encouraging
for checkpoint resistant metastatic melanoma patients who currently
rely on systemic administration of immune-stimulating drugs
associated with severe toxicity," said Paolo A. Ascierto, M.D., Director of the Unit of
Melanoma, Cancer Immunotherapy and Innovative Therapy at the
National Tumor Institute Fondazione G. Pascale in Naples, Italy. "The data reported, in addition
to its ease of use, demonstrate the potential of TAVO in
combination with pembrolizumab as a next-generation intratumoral
IL-12 therapy that can induce regression of both locally treated
and untreated distant and visceral lesions."
OncoSec's presentation is summarized below:
Introduction
Presenter: Christopher G. Twitty, Ph.D.
Session Date/Time: Saturday, April
17, 2021, 4:15 p.m. –
4:18 p.m. ET
OncoSec's KEYNOTE-695 interim data
Presenter:
Paolo Ascierto, M.D.
Session Date/Time: Saturday, April
17, 2021, 4:18 p.m. –
4:28 p.m. ET
OncoSec's next generation therapies: amplification of the
CRX3/CXCL9 axis via intratumoral electroporation of CXCL9
synergizes with IL-12 therapy (TAVO) to elicit robust anti-tumor
immunity
Presenter: Christopher G. Twitty,
Ph.D.
Session Date/Time: Saturday, April
17, 2021, 4:28 p.m. –
4:48 p.m. ET
Live Q&A
Presenters: Christopher G. Twitty, Ph.D., Paolo Ascierto, M.D.
Session Date/Time: Saturday, April
17, 4:48 p.m. – 5:15 p.m. ET
The conference will be held virtually from April 15 – 17, 2021. To access the conference
virtual platform, visit:
https://worldmelanoma2021.com/login-virtual-platform.
About KEYNOTE-695
KEYNOTE-695 is OncoSec's
registration-directed Phase 2b trial
(NCT#03132675) evaluating TAVO™ (tavokinogene telseplasmid), a DNA
plasmid-based interleukin-12 (IL-12) + KEYTRUDA® (pembrolizumab) in
patients with rigorously confirmed anti-PD-1 checkpoint resistant
metastatic melanoma. The trial aims to enroll up to 100 patients
with refractory, locally advanced or metastatic disease defined as
unresectable Stage III/IV metastatic melanoma that had definitively
progressed on a full-course of anti-PD-1 treatment with KEYTRUDA®
(pembrolizumab) or OPDIVO® (nivolumab). TAVO™ has received Fast
Track Designation from the U.S. Food and Drug Administration (FDA)
for the treatment of metastatic melanoma following progression on
KEYTRUDA or OPDIVO.
About TAVO™
OncoSec's gene therapy technology combines TAVO (tavokinogene
telseplasmid), a DNA plasmid-based interleukin-12 (IL-12), with an
intra-tumoral electroporation gene delivery platform to achieve
endogenous IL-12 production in the tumor microenvironment that
enables the immune system to target and attack tumors throughout
the body. TAVO has demonstrated a local and systemic
anti-tumor response in several clinical trials, including the
pivotal Phase 2b trial KEYNOTE-695
for metastatic melanoma and the KEYNOTE-890 Phase 2 trial in triple
negative breast cancer (TNBC). TAVO™ has received both Orphan Drug
and Fast-Track Designation by the U.S. Food & Drug
Administration for the treatment of metastatic melanoma.
About OncoSec Medical Incorporated
OncoSec Medical Incorporated (the "Company," "OncoSec," "we" or
"our") is a biotechnology company focused on developing
cytokine-based intratumoral immunotherapies to stimulate the body's
immune system to target and attack cancer. OncoSec's lead
immunotherapy investigational product candidate – TAVO™
(tavokinogene telseplasmid) – enables the intratumoral delivery of
DNA-based interleukin-12 (IL-12), a naturally occurring protein
with immune-stimulating functions. The technology, which employs
electroporation, is designed to produce a controlled, localized
expression of IL-12 in the tumor microenvironment, enabling the
immune system to target and attack tumors throughout the body.
OncoSec has built a deep and diverse clinical pipeline utilizing
TAVO™ as a potential treatment for multiple cancer indications
either as a monotherapy or in combination with leading checkpoint
inhibitors; with the latter potentially enabling OncoSec to address
a great unmet medical need in oncology: anti-PD-1 non-responders.
Results from recently completed clinical studies of TAVO™ have
demonstrated a local immune response, and subsequently, a systemic
effect as either a monotherapy or combination treatment approach
along with an acceptable safety profile, warranting further
development. In addition to TAVO™, OncoSec is identifying and
developing new DNA-encoded therapeutic candidates and tumor
indications for use with its new Visceral Lesion Applicator (VLA),
to target deep visceral lesions, such as liver, lung or pancreatic
lesions. For more information, please visit www.oncosec.com.
TAVO™ is a trademark of OncoSec Medical Incorporated.
Company Contact
Brian
Leuthner
Chief Operating Officer
investors@oncosec.com
Media Contact
Patrick
Bursey
LifeSci Communications
+1-646-970-4688
pbursey@lifescicomms.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/oncosec-to-present-encore-interim-data-from-the-keynote-695-phase-2b-clinical-trial-at-the-10th-world-congress-of-melanoma-301269801.html
SOURCE OncoSec Medical Incorporated